Inclusion criteria :

          -  Participants must be ≥ 18 years of age

          -  Histologically proven diagnosis of advanced solid tumors

          -  Participants must have one or more of the following molecular aberrations (Part 1):
             KRAS mutations and amplifications, BRAF Class 3 mutations, or NF1 LOF mutations

          -  At least 1 measurable disease per RECIST 1.1 criteria.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Woman of childbearing potential must agree to follow contraceptive guidance

          -  Capable of giving signed informed consent

        Exclusion criteria:

          -  Predicted life expectancy <3 months.

          -  Primary central nervous system (CNS) tumors.

          -  Symptomatic or impending cord compression.

          -  History of cerebrovascular stroke or transient ischemic attack within previous 6
             months.

          -  Prior solid organ or hematologic transplant.

          -  History or current retinal pigment epithelial detachment (RPED), central serous
             retinopathy, retinal vascular occlusion (RVO), neovascular macular degeneration

          -  Any clinically significant cardiac disease

          -  Active, known or suspected autoimmune disease

          -  History of or current interstitial lung disease or pneumonitis

          -  Receipt of a live-virus vaccination within 28 days of planned treatment start

          -  Known infection with human immunodeficiency virus (HIV), known uncontrolled hepatitis
             B infection, active tuberculosis, or severe infection requiring parenteral antibiotic
             treatment.

          -  Inadequate hematologic, hepatic and renal function

          -  Known second malignancy

          -  Impairment of gastrointestinal function

          -  Any unstable or clinically significant concurrent medical condition that would, in the
             opinion of the investigator, jeopardize the safety of a participant, impact their
             expected survival through the end of the study participation, and/or impact their
             ability to comply with the protocol.

          -  History of severe allergic reaction to any of the study intervention components

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.